Literature DB >> 12748197

p38 Mitogen-activated protein kinase regulation of JB6 Cl41 cell transformation promoted by epidermal growth factor.

Zhiwei He1, Yong-Yeon Cho, Guangming Liu, Wei-Ya Ma, Ann M Bode, Zigang Dong.   

Abstract

The relationship between cell transformation and p38 MAP kinase, a major mitogen-activated protein (MAP) kinase pathway converting signals of various extracellular stimuli into expression of specific target genes through activation of transcription factors, still remains unclear. The aim of the present study was to investigate the role of the p38 MAP kinase pathway in epidermal growth factor (EGF)-induced cell transformation in JB6 cells. Our data show that a dominant negative mutant of p38 MAP (DN-p38) kinase inhibits EGF-promoted JB6 Cl41 cell transformation and that SB202190, an inhibitor of p38 MAP kinase, also inhibits JB6 Cl41 cell transformation in a dose-dependent manner. Moreover, our results show that DN-p38 MAP kinase inhibits the phosphorylation of EGF-stimulated activating transcription factor-2 (ATF-2) and signal transducer and activator of transcription 1 (STAT1). Additionally, DN-p38 MAP kinase inhibits EGF-induced phosphorylation of c-Myc (Thr58/Ser62). Gel shift assays indicate that DN-p38 MAP kinase inhibits EGF-induced activator protein-1 (AP-1) DNA binding in a dose-dependent manner. These results show that p38 MAP kinase plays a key role in the regulation of EGF-induced cell transformation in JB6 cells through regulation of phosphorylation of p38 MAP kinase and activation of its target genes in phosphorylation, c-Myc cell transformation-related genes, and AP-1 binding ability.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12748197     DOI: 10.1074/jbc.M303859200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Effects of MAP kinase inhibitors on epidermal growth factor-induced neoplastic transformation of human keratinocytes.

Authors:  Hideya Mizuno; Yong-Yeon Cho; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-01       Impact factor: 4.784

2.  Mitogen- and stress-activated kinase 1-mediated histone H3 phosphorylation is crucial for cell transformation.

Authors:  Hong-Gyum Kim; Ki Won Lee; Yong-Yeon Cho; Nam Joo Kang; Sang-Muk Oh; Ann M Bode; Zigang Dong
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

3.  Fyn is a novel target of (-)-epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation.

Authors:  Zhiwei He; Faqing Tang; Svetlana Ermakova; Ming Li; Qing Zhao; Yong-Yeon Cho; Wei-Ya Ma; Hong-Seok Choi; Ann M Bode; Chung S Yang; Zigang Dong
Journal:  Mol Carcinog       Date:  2008-03       Impact factor: 4.784

4.  Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells.

Authors:  R S Watnick; R K Rodriguez; S Wang; A L Blois; A Rangarajan; T Ince; R A Weinberg
Journal:  Oncogene       Date:  2014-08-11       Impact factor: 9.867

5.  Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at Ser63 and Ser73 enhances cell transformation.

Authors:  Yong-Yeon Cho; Faqing Tang; Ke Yao; Chengrong Lu; Feng Zhu; Duo Zheng; Angelo Pugliese; Ann M Bode; Zigang Dong
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

6.  Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190.

Authors:  Naval P Shanware; Leah M Williams; Michael J Bowler; Randal S Tibbetts
Journal:  BMB Rep       Date:  2009-03-31       Impact factor: 4.778

7.  Bakuchiol suppresses proliferation of skin cancer cells by directly targeting Hck, Blk, and p38 MAP kinase.

Authors:  Jong-Eun Kim; Jae Hwan Kim; Younghyun Lee; Hee Yang; Yong-Seok Heo; Ann M Bode; Ki Won Lee; Zigang Dong
Journal:  Oncotarget       Date:  2016-03-22

8.  Fibroblast growth factor receptor is a mechanistic link between visceral adiposity and cancer.

Authors:  D Chakraborty; V Benham; B Bullard; T Kearney; H C Hsia; D Gibbon; E Y Demireva; S Y Lunt; J J Bernard
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.